Saturday 17 October 2026
Export IVPR’s income statement to Excel — free account
Inspire Veterinary Partners, Inc.
IVPR Consumer Cyclical Personal Services
Inspire Veterinary Partners, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $16.6 million, roughly unchanged from fiscal 2023. In the quarter to September 2025, revenue grew 6.60%, EPS grew 51.7% and free cash flow grew 79.1%, each against the same quarter a year earlier.
0.00
0.00
NaN
Follow IVPR
| Sep '25 | Jun '25 | Mar '25 | Dec '24 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.38 | 0.67 | 0.62 | 1.60 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(4.65) | (11.35) | (6.91) | (39.24) | |
P/B ratio |
1.43 | 22.84 | 3.16 | 17.02 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.73 | 1.21 | 1.04 | 2.08 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(2.67) | (2.00) | (1.95) | (3.45) | |
EV/FCF |
(1.96) | (1.72) | (1.65) | (2.96) | |
Quick Ratio |
0.30 | 0.03 | 0.23 | 0.07 | |
Current Ratio |
0.39 | 0.13 | 0.39 | 0.25 | |
Net Debt/EBITDA |
(4.50) | (4.11) | (4.72) | (7.81) | |
Debt/Assets |
34.46% | 40.63% | 40.09% | 42.04% | |
Debt/Equity |
1.98 | 18.95 | 2.76 | 5.44 | |
Asset Turnover |
0.67 | 0.72 | 0.70 | 0.79 | |
Operating CF/Net income |
0.51 | 0.30 | 0.57 | 0.16 | |
Capex/Depreciation |
(0.06) | (0.02) | (0.03) | (0.06) | |
Interest Coverage |
(3.52) | (6.24) | (4.92) | (5.17) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
56.15% | 61.87% | 67.22% | 100.61% | |
Intangible Assets out of Total Assets |
0.43 | 0.50 | 0.46 | 0.48 | |
Share Based Compensation of Revenue |
0.00% | 3.25% | 0.00% | 0.00% | |
Graham Net Nets |
(2.67) | (1.87) | (1.55) | (0.62) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(224.49%) | (156.12%) | (166.13%) | (68.68%) | |
Free Cash Flow Yield |
(96.70%) | (105.76%) | (102.57%) | (43.91%) | |
Revenue per Share |
0.71 | 0.71 | 0.66 | 0.60 | |
Operating CF per Share |
(0.21) | (0.15) | (0.25) | (0.12) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | (0.01) | |
Free Cash Flow per Share |
(0.22) | (0.15) | (0.25) | (0.13) | |
Cash per Share |
0.48 | 0.03 | 0.31 | 0.09 | |
Shareholders Equity per Share |
0.68 | 0.07 | 0.54 | 0.28 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.68 | 0.07 | 0.54 | 0.28 | |
Free Cash Flow |
(1.33) | (0.91) | (1.39) | (0.71) | |
Working Capital |
(5.89) | (8.72) | (4.57) | (6.18) | |
Capital Expenditures |
(0.04) | (0.01) | (0.02) | (0.03) | |
Net Current Asset Value |
(15.96) | (19.03) | (14.76) | (16.61) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.00 | 0.01 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.07 | 0.11 | 0.25 | 0.13 | |
Average Payables |
1.89 | 2.80 | 2.65 | 2.59 | |
Average Inventory |
0.53 | 0.53 | 0.51 | 0.54 | |
Average Assets |
23.18 | 21.37 | 22.03 | 20.99 | |
Average Common Equity |
3.60 | (1.33) | 1.64 | 0.39 |
Columns are period end dates